Information Library

Brochures - Lifecycle Safety

To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.

See all

  • Sort by:
  • Most Recent
  • Title

  • The New Health Clinical Brochure

    August 31, 2010
    Japanese version available for download.

  • Targeting Oncology

    June 2, 2010
    Learn more about Quintiles leadership in oncology product development and commercialization.

  • Clinical – smarter trials, accelerated outcomes

    April 2, 2010
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • Patient Registries

    December 11, 2009
    Patient registries services to proof efficacy & safety of drugs through real-life patient data.

  • Reinventing Safety: A New Standard for Risk-Benefit Management

    December 1, 2009
    When you integrate all your safety information, you can make better decisions, navigate regulatory hurdles and get to market faster.

  • Risk Mitigation Programs

    April 16, 2009
    Risk mitigation measures can help keep valuable drugs on the market, even when their safety profile includes adverse events that might negatively affect the benefit risk balance.

  • Risk Assessment & Strategy

    April 16, 2009
    Quintiles benefit risk analysis can help you anticipate potential regulatory concerns and highlight the benefit side of your drug’s benefit risk profile.

  • Phase IIIb/IV Studies

    April 16, 2009
    New, more efficient delivery models help meet the increasing demands of Phase IIIB/IV Studies.

  • Late Phase and Safety Services

    April 10, 2009
    Recent and pending regulatory changes have created an atmosphere of watchful waiting throughout the industry. While it may seem premature to initiate post-marketing studies to collect more “intelligent” safety data, Quintiles Late Phase & Safety Services anticipates that the need for expanded studies will soon spread.

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences